Categories: News

EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Full-Year 2024 Results
Conference Call Invitation

Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer,
Mr PAUL DU SAILLANT, Deputy Chief Executive Officer,
Mr STEFANO GRASSI, Chief Financial Officer, and
Mr GIORGIO IANNELLA, Head of Investor Relations,
have the pleasure of inviting you to our Full-Year 2024 Results Conference Call on:

Wednesday, February 12, 2025, at 6:30 pm CET

Dial-in telephone access:

If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID):

https://grid.trustwavetechnology.com/essilorluxottica/register.html

If you encounter any issue in the pre-registration phase you may contact ir@essilorluxottica.com, providing your name and surname and the name of your company.

Live webcast:

You can watch the presentation at the following link:

https://streamstudio.world-television.com/1217-2090-41194/en

The press release will be published at 6:00 pm CET on the same day and the presentation slides will be made available prior to the call. Both can be found on https://www.essilorluxottica.com/investors.

Attachment

Staff

Recent Posts

ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing

HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization…

26 minutes ago

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic…

26 minutes ago

Trump May Reclassify Marijuana – MMJ BioPharma To Escape The DEA’s Seven Year Cannabis Trial Roadblock?

Trump said his administration will focus on research to unlock the medical uses of marijuana,…

26 minutes ago

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY…

3 hours ago

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for…

6 hours ago